MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Yoshimi Endo Greer, Samuel F. Gilbert, Brunilde Gril, Rajesh Narwal, Danielle L. Peacock Brooks, David A. Tice, Patricia S. Steeg, Stanley Lipkowitz

ABSTRACT

BACKGROUND: TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists are attractive anti-tumor agents because of their capability to induce apoptosis in cancer cells by activating death receptors (DR) 4 and 5 with little toxicity against normal cells. Despite an attractive mechanism of action, previous clinical efforts to use TRAIL receptor agonists have been unsuccessful. In this study, we examined MEDI3039, a highly potent multivalent DR5 agonist, in breast cancer cell lines and in vivo models. METHODS: As in vitro model systems, we used 19 breast cancer cell lines that are categorized into four subtypes: ER+, HER2 amplified, basal A (triple-negative breast cancer) TNBC, and basal B TNBC. Cell viability was analyzed by MTS and RealTime live/dead assays. As in vivo model systems, MDA-MB231T orthotopic primary tumor growth in the mammary fat pad (MFP) and two experimental lung metastasis models were used. The effect of MEDI3039 on MFP tumors was assessed with immunohistochemical analysis. Lung metastases were analyzed with Bouin's and H&E staining. RESULTS: MEDI3039 killed multiple breast cancer cell lines, but the sensitivity varied among different subtypes. Sensitivity was basal B TNBC >> basal A TNBC > HER2 amplified > ER+ (average IC50 = 1.4, 203, 314, 403 pM, respectively). While the pattern of relative sensitivity was similar to GST-TRAIL in most cell lines, MEDI3039 was at least two orders of magnitude more potent compared with GST-TRAIL. In the MFP model, weekly treatment with 0.1 or 0.3 mg/kg MEDI3039 for 5 weeks inhibited tumor growth by 99.05% or 100% (median), respectively, compared with the control group, and extended animal survival (p = 0.08 or p = 0.0032 at 0.1 or 0.3 mg/kg, respectively). MEDI3039-induced caspase activation was confirmed in tumors grown in MFP (p < 0.05). In an experimental pulmonary metastasis model, MEDI3039 significantly suppressed outgrowth of surface (p < 0.0001) and microscopic metastases (p < 0.05). In an established lung metastasis model, MEDI3039 significantly inhibited growth of metastases (p < 0.01 in surface [> 4 mm], p < 0.01 in tumor percentage) and extended animal survival (p < 0.0001). CONCLUSION: MEDI3039 is a potent DR5 agonist in breast cancer cells in vitro and in vivo and has potential as a cancer drug in breast cancer patients, especially those with basal B TNBC. More... »

PAGES

27

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1

DOI

http://dx.doi.org/10.1186/s13058-019-1116-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112212889

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30777098


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Center for Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.417768.b", 
          "name": [
            "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greer", 
        "givenName": "Yoshimi Endo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.417768.b", 
          "name": [
            "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gilbert", 
        "givenName": "Samuel F.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.417768.b", 
          "name": [
            "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gril", 
        "givenName": "Brunilde", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune, LLC, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narwal", 
        "givenName": "Rajesh", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.417768.b", 
          "name": [
            "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peacock Brooks", 
        "givenName": "Danielle L.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune, LLC, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tice", 
        "givenName": "David A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.417768.b", 
          "name": [
            "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steeg", 
        "givenName": "Patricia S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.417768.b", 
          "name": [
            "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lipkowitz", 
        "givenName": "Stanley", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.molonc.2010.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000679392"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-0099", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002263531"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-008-9924-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004175549", 
          "https://doi.org/10.1007/s10549-008-9924-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-008-9924-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004175549", 
          "https://doi.org/10.1007/s10549-008-9924-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-12-1107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007777257"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.molcel.2009.05.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009338658"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2011.456", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010106674", 
          "https://doi.org/10.1038/bjc.2011.456"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2016.66", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011587927", 
          "https://doi.org/10.1038/nrclinonc.2016.66"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/dji111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012123441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-14-2780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018580324"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14728222.2010.519701", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019091862"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.25.1991", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019828190"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.cdd.4402306", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019980757", 
          "https://doi.org/10.1038/sj.cdd.4402306"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci80420", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022292043"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-1692", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024329711"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature11412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024942368", 
          "https://doi.org/10.1038/nature11412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0065-230x(06)96008-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028038077"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr2945", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030462236", 
          "https://doi.org/10.1186/bcr2945"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/gco.0000000000000239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033356012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/gco.0000000000000239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033356012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2014.04.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033537828"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2014.04.028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033537828"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35021093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033846543", 
          "https://doi.org/10.1038/35021093"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev-bioeng-112415-114722", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035945779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/459334a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036855676", 
          "https://doi.org/10.1038/459334a"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/459334a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036855676", 
          "https://doi.org/10.1038/459334a"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci45014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037799511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0065-230x(09)03003-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038528751"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0075414", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039471372"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2006.10.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040586971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-015-3673-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043457677", 
          "https://doi.org/10.1007/s10549-015-3673-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2010.221", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043860701", 
          "https://doi.org/10.1038/onc.2010.221"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2010.221", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043860701", 
          "https://doi.org/10.1038/onc.2010.221"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046245271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1739", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048794721", 
          "https://doi.org/10.1038/nrc1739"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1739", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048794721", 
          "https://doi.org/10.1038/nrc1739"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1739", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048794721", 
          "https://doi.org/10.1038/nrc1739"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050616550", 
          "https://doi.org/10.1038/nature08012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature08012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050616550", 
          "https://doi.org/10.1038/nature08012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-009-0571-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051612647", 
          "https://doi.org/10.1007/s10549-009-0571-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cytogfr.2013.12.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052221635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m115.713545", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058214598"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/ten.tea.2010.0273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059315652"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.1279805", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062471450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.3845", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14712590903319656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067588039"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/cbt.6.9.4905", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072294727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074882356", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.170.9.4854", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075280428"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-17-1029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091249666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7554/elife.30224", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100468486"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7554/elife.30224", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100468486"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/his.13528", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103268269"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists are attractive anti-tumor agents because of their capability to induce apoptosis in cancer cells by activating death receptors (DR) 4 and 5 with little toxicity against normal cells. Despite an attractive mechanism of action, previous clinical efforts to use TRAIL receptor agonists have been unsuccessful. In this study, we examined MEDI3039, a highly potent multivalent DR5 agonist, in breast cancer cell lines and in vivo models.\nMETHODS: As in vitro model systems, we used 19 breast cancer cell lines that are categorized into four subtypes: ER+, HER2 amplified, basal A (triple-negative breast cancer) TNBC, and basal B TNBC. Cell viability was analyzed by MTS and RealTime live/dead assays. As in vivo model systems, MDA-MB231T orthotopic primary tumor growth in the mammary fat pad (MFP) and two experimental lung metastasis models were used. The effect of MEDI3039 on MFP tumors was assessed with immunohistochemical analysis. Lung metastases were analyzed with Bouin's and H&E staining.\nRESULTS: MEDI3039 killed multiple breast cancer cell lines, but the sensitivity varied among different subtypes. Sensitivity was basal B TNBC >> basal A TNBC > HER2 amplified > ER+ (average IC50\u2009=\u20091.4, 203, 314, 403\u2009pM, respectively). While the pattern of relative sensitivity was similar to GST-TRAIL in most cell lines, MEDI3039 was at least two orders of magnitude more potent compared with GST-TRAIL. In the MFP model, weekly treatment with 0.1 or 0.3\u2009mg/kg MEDI3039 for 5\u2009weeks inhibited tumor growth by 99.05% or 100% (median), respectively, compared with the control group, and extended animal survival (p\u2009=\u20090.08 or p\u2009=\u20090.0032 at 0.1 or 0.3\u2009mg/kg, respectively). MEDI3039-induced caspase activation was confirmed in tumors grown in MFP (p\u2009<\u20090.05). In an experimental pulmonary metastasis model, MEDI3039 significantly suppressed outgrowth of surface (p\u2009<\u20090.0001) and microscopic metastases (p\u2009<\u20090.05). In an established lung metastasis model, MEDI3039 significantly inhibited growth of metastases (p\u2009<\u20090.01 in surface [>\u20094\u2009mm], p\u2009<\u20090.01 in tumor percentage) and extended animal survival (p\u2009<\u20090.0001).\nCONCLUSION: MEDI3039 is a potent DR5 agonist in breast cancer cells in vitro and in vivo and has potential as a cancer drug in breast cancer patients, especially those with basal B TNBC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13058-019-1116-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2722431", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2726375", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1022375", 
        "issn": [
          "1465-5411", 
          "1465-542X"
        ], 
        "name": "Breast Cancer Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "name": "MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer", 
    "pagination": "27", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "14a8cf5ce08720a4c6cc4f6512e302e9b078b9497f084585ce9de52031d28587"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30777098"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100927353"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13058-019-1116-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112212889"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13058-019-1116-1", 
      "https://app.dimensions.ai/details/publication/pub.1112212889"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000358_0000000358/records_127432_00000011.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13058-019-1116-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1'


 

This table displays all metadata directly associated to this object as RDF triples.

261 TRIPLES      21 PREDICATES      73 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13058-019-1116-1 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N6b7f18fd2e12457da663aa907d303c76
4 schema:citation sg:pub.10.1007/s10549-008-9924-5
5 sg:pub.10.1007/s10549-009-0571-2
6 sg:pub.10.1007/s10549-015-3673-z
7 sg:pub.10.1038/35021093
8 sg:pub.10.1038/459334a
9 sg:pub.10.1038/bjc.2011.456
10 sg:pub.10.1038/nature08012
11 sg:pub.10.1038/nature11412
12 sg:pub.10.1038/nrc1739
13 sg:pub.10.1038/nrclinonc.2016.66
14 sg:pub.10.1038/onc.2010.221
15 sg:pub.10.1038/sj.cdd.4402306
16 sg:pub.10.1186/bcr2945
17 https://app.dimensions.ai/details/publication/pub.1074882356
18 https://doi.org/10.1016/j.ccr.2006.10.008
19 https://doi.org/10.1016/j.ccr.2014.04.028
20 https://doi.org/10.1016/j.cytogfr.2013.12.009
21 https://doi.org/10.1016/j.molcel.2009.05.001
22 https://doi.org/10.1016/j.molonc.2010.11.003
23 https://doi.org/10.1016/s0065-230x(06)96008-4
24 https://doi.org/10.1016/s0065-230x(09)03003-6
25 https://doi.org/10.1074/jbc.m115.713545
26 https://doi.org/10.1089/ten.tea.2010.0273
27 https://doi.org/10.1093/annonc/mdn015
28 https://doi.org/10.1093/jnci/dji111
29 https://doi.org/10.1097/gco.0000000000000239
30 https://doi.org/10.1111/his.13528
31 https://doi.org/10.1126/science.1279805
32 https://doi.org/10.1146/annurev-bioeng-112415-114722
33 https://doi.org/10.1158/1078-0432.ccr-09-1692
34 https://doi.org/10.1158/1078-0432.ccr-11-0099
35 https://doi.org/10.1158/1078-0432.ccr-14-2780
36 https://doi.org/10.1158/1078-0432.ccr-17-1029
37 https://doi.org/10.1158/1535-7163.mct-12-1107
38 https://doi.org/10.1172/jci45014
39 https://doi.org/10.1172/jci80420
40 https://doi.org/10.1200/jco.2005.03.3845
41 https://doi.org/10.1200/jco.2009.25.1991
42 https://doi.org/10.1371/journal.pone.0075414
43 https://doi.org/10.1517/14712590903319656
44 https://doi.org/10.1517/14728222.2010.519701
45 https://doi.org/10.4049/jimmunol.170.9.4854
46 https://doi.org/10.4161/cbt.6.9.4905
47 https://doi.org/10.7554/elife.30224
48 schema:datePublished 2019-12
49 schema:datePublishedReg 2019-12-01
50 schema:description BACKGROUND: TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists are attractive anti-tumor agents because of their capability to induce apoptosis in cancer cells by activating death receptors (DR) 4 and 5 with little toxicity against normal cells. Despite an attractive mechanism of action, previous clinical efforts to use TRAIL receptor agonists have been unsuccessful. In this study, we examined MEDI3039, a highly potent multivalent DR5 agonist, in breast cancer cell lines and in vivo models. METHODS: As in vitro model systems, we used 19 breast cancer cell lines that are categorized into four subtypes: ER+, HER2 amplified, basal A (triple-negative breast cancer) TNBC, and basal B TNBC. Cell viability was analyzed by MTS and RealTime live/dead assays. As in vivo model systems, MDA-MB231T orthotopic primary tumor growth in the mammary fat pad (MFP) and two experimental lung metastasis models were used. The effect of MEDI3039 on MFP tumors was assessed with immunohistochemical analysis. Lung metastases were analyzed with Bouin's and H&E staining. RESULTS: MEDI3039 killed multiple breast cancer cell lines, but the sensitivity varied among different subtypes. Sensitivity was basal B TNBC >> basal A TNBC > HER2 amplified > ER+ (average IC50 = 1.4, 203, 314, 403 pM, respectively). While the pattern of relative sensitivity was similar to GST-TRAIL in most cell lines, MEDI3039 was at least two orders of magnitude more potent compared with GST-TRAIL. In the MFP model, weekly treatment with 0.1 or 0.3 mg/kg MEDI3039 for 5 weeks inhibited tumor growth by 99.05% or 100% (median), respectively, compared with the control group, and extended animal survival (p = 0.08 or p = 0.0032 at 0.1 or 0.3 mg/kg, respectively). MEDI3039-induced caspase activation was confirmed in tumors grown in MFP (p < 0.05). In an experimental pulmonary metastasis model, MEDI3039 significantly suppressed outgrowth of surface (p < 0.0001) and microscopic metastases (p < 0.05). In an established lung metastasis model, MEDI3039 significantly inhibited growth of metastases (p < 0.01 in surface [> 4 mm], p < 0.01 in tumor percentage) and extended animal survival (p < 0.0001). CONCLUSION: MEDI3039 is a potent DR5 agonist in breast cancer cells in vitro and in vivo and has potential as a cancer drug in breast cancer patients, especially those with basal B TNBC.
51 schema:genre research_article
52 schema:inLanguage en
53 schema:isAccessibleForFree true
54 schema:isPartOf Naa5aa710075241e8984b9e342a70b3dd
55 Nea0b9e6233684beb88730f9e16f24997
56 sg:journal.1022375
57 schema:name MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer
58 schema:pagination 27
59 schema:productId N41c11b0ffb7d444a8e1698b5a59a5ae4
60 N7d594647f3e74d2995d8f040069cc250
61 N9f57a0f3463b4700a95e0ba499765d90
62 Nadeb159e4ec34f6283e094cfda61260f
63 Nfcad3e9198514dce960b4c9a88163c1f
64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112212889
65 https://doi.org/10.1186/s13058-019-1116-1
66 schema:sdDatePublished 2019-04-11T11:38
67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
68 schema:sdPublisher Nb84cc6f647fb4d7d8884610b23828f6a
69 schema:url https://link.springer.com/10.1186%2Fs13058-019-1116-1
70 sgo:license sg:explorer/license/
71 sgo:sdDataset articles
72 rdf:type schema:ScholarlyArticle
73 N06aff12b87774deb8638c2d364279541 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
74 schema:familyName Narwal
75 schema:givenName Rajesh
76 rdf:type schema:Person
77 N1b6c498dcd6441f081263a67e1c63b9b schema:affiliation https://www.grid.ac/institutes/grid.417768.b
78 schema:familyName Lipkowitz
79 schema:givenName Stanley
80 rdf:type schema:Person
81 N2860347f830a453eb4eceef5d84ae2f9 schema:affiliation https://www.grid.ac/institutes/grid.417768.b
82 schema:familyName Greer
83 schema:givenName Yoshimi Endo
84 rdf:type schema:Person
85 N3606f3fcc0864b9eb29af11d228c55c0 rdf:first Ne7cb73694d704fae912d0debc6dd485a
86 rdf:rest N5f39e81c1ab54a9cb5bac034fc184710
87 N41c11b0ffb7d444a8e1698b5a59a5ae4 schema:name readcube_id
88 schema:value 14a8cf5ce08720a4c6cc4f6512e302e9b078b9497f084585ce9de52031d28587
89 rdf:type schema:PropertyValue
90 N5f39e81c1ab54a9cb5bac034fc184710 rdf:first Nfde837ecbf224fa5899be2ba96da816d
91 rdf:rest Neb6bef8e6b2b41d1816036f04938ade7
92 N6b7f18fd2e12457da663aa907d303c76 rdf:first N2860347f830a453eb4eceef5d84ae2f9
93 rdf:rest N8d43fe99142a413b97af67b6637a452c
94 N7d594647f3e74d2995d8f040069cc250 schema:name doi
95 schema:value 10.1186/s13058-019-1116-1
96 rdf:type schema:PropertyValue
97 N84432bcf7d124706b3c7609607de8360 schema:affiliation https://www.grid.ac/institutes/grid.417768.b
98 schema:familyName Steeg
99 schema:givenName Patricia S.
100 rdf:type schema:Person
101 N8a4acae8127346c99c42ae8772be0ce6 rdf:first N1b6c498dcd6441f081263a67e1c63b9b
102 rdf:rest rdf:nil
103 N8d43fe99142a413b97af67b6637a452c rdf:first Nfeb08efbd8894d54a41b88515395cab8
104 rdf:rest Nc06891e56c324f78a2a080f44ff53b17
105 N9f57a0f3463b4700a95e0ba499765d90 schema:name pubmed_id
106 schema:value 30777098
107 rdf:type schema:PropertyValue
108 Naa5aa710075241e8984b9e342a70b3dd schema:volumeNumber 21
109 rdf:type schema:PublicationVolume
110 Nadeb159e4ec34f6283e094cfda61260f schema:name dimensions_id
111 schema:value pub.1112212889
112 rdf:type schema:PropertyValue
113 Nb180c4e2170e4b4ebd6f3f2f54474da1 rdf:first N06aff12b87774deb8638c2d364279541
114 rdf:rest N3606f3fcc0864b9eb29af11d228c55c0
115 Nb84cc6f647fb4d7d8884610b23828f6a schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 Nc06891e56c324f78a2a080f44ff53b17 rdf:first Nf95666d5a9b244879175e075bd5695cc
118 rdf:rest Nb180c4e2170e4b4ebd6f3f2f54474da1
119 Ne7cb73694d704fae912d0debc6dd485a schema:affiliation https://www.grid.ac/institutes/grid.417768.b
120 schema:familyName Peacock Brooks
121 schema:givenName Danielle L.
122 rdf:type schema:Person
123 Nea0b9e6233684beb88730f9e16f24997 schema:issueNumber 1
124 rdf:type schema:PublicationIssue
125 Neb6bef8e6b2b41d1816036f04938ade7 rdf:first N84432bcf7d124706b3c7609607de8360
126 rdf:rest N8a4acae8127346c99c42ae8772be0ce6
127 Nf95666d5a9b244879175e075bd5695cc schema:affiliation https://www.grid.ac/institutes/grid.417768.b
128 schema:familyName Gril
129 schema:givenName Brunilde
130 rdf:type schema:Person
131 Nfcad3e9198514dce960b4c9a88163c1f schema:name nlm_unique_id
132 schema:value 100927353
133 rdf:type schema:PropertyValue
134 Nfde837ecbf224fa5899be2ba96da816d schema:affiliation https://www.grid.ac/institutes/grid.418152.b
135 schema:familyName Tice
136 schema:givenName David A.
137 rdf:type schema:Person
138 Nfeb08efbd8894d54a41b88515395cab8 schema:affiliation https://www.grid.ac/institutes/grid.417768.b
139 schema:familyName Gilbert
140 schema:givenName Samuel F.
141 rdf:type schema:Person
142 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
143 schema:name Medical and Health Sciences
144 rdf:type schema:DefinedTerm
145 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
146 schema:name Oncology and Carcinogenesis
147 rdf:type schema:DefinedTerm
148 sg:grant.2722431 http://pending.schema.org/fundedItem sg:pub.10.1186/s13058-019-1116-1
149 rdf:type schema:MonetaryGrant
150 sg:grant.2726375 http://pending.schema.org/fundedItem sg:pub.10.1186/s13058-019-1116-1
151 rdf:type schema:MonetaryGrant
152 sg:journal.1022375 schema:issn 1465-5411
153 1465-542X
154 schema:name Breast Cancer Research
155 rdf:type schema:Periodical
156 sg:pub.10.1007/s10549-008-9924-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004175549
157 https://doi.org/10.1007/s10549-008-9924-5
158 rdf:type schema:CreativeWork
159 sg:pub.10.1007/s10549-009-0571-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051612647
160 https://doi.org/10.1007/s10549-009-0571-2
161 rdf:type schema:CreativeWork
162 sg:pub.10.1007/s10549-015-3673-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1043457677
163 https://doi.org/10.1007/s10549-015-3673-z
164 rdf:type schema:CreativeWork
165 sg:pub.10.1038/35021093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033846543
166 https://doi.org/10.1038/35021093
167 rdf:type schema:CreativeWork
168 sg:pub.10.1038/459334a schema:sameAs https://app.dimensions.ai/details/publication/pub.1036855676
169 https://doi.org/10.1038/459334a
170 rdf:type schema:CreativeWork
171 sg:pub.10.1038/bjc.2011.456 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010106674
172 https://doi.org/10.1038/bjc.2011.456
173 rdf:type schema:CreativeWork
174 sg:pub.10.1038/nature08012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050616550
175 https://doi.org/10.1038/nature08012
176 rdf:type schema:CreativeWork
177 sg:pub.10.1038/nature11412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024942368
178 https://doi.org/10.1038/nature11412
179 rdf:type schema:CreativeWork
180 sg:pub.10.1038/nrc1739 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048794721
181 https://doi.org/10.1038/nrc1739
182 rdf:type schema:CreativeWork
183 sg:pub.10.1038/nrclinonc.2016.66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011587927
184 https://doi.org/10.1038/nrclinonc.2016.66
185 rdf:type schema:CreativeWork
186 sg:pub.10.1038/onc.2010.221 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043860701
187 https://doi.org/10.1038/onc.2010.221
188 rdf:type schema:CreativeWork
189 sg:pub.10.1038/sj.cdd.4402306 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019980757
190 https://doi.org/10.1038/sj.cdd.4402306
191 rdf:type schema:CreativeWork
192 sg:pub.10.1186/bcr2945 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030462236
193 https://doi.org/10.1186/bcr2945
194 rdf:type schema:CreativeWork
195 https://app.dimensions.ai/details/publication/pub.1074882356 schema:CreativeWork
196 https://doi.org/10.1016/j.ccr.2006.10.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040586971
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/j.ccr.2014.04.028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033537828
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/j.cytogfr.2013.12.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052221635
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/j.molcel.2009.05.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009338658
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/j.molonc.2010.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000679392
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/s0065-230x(06)96008-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028038077
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/s0065-230x(09)03003-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038528751
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1074/jbc.m115.713545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058214598
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1089/ten.tea.2010.0273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059315652
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1093/annonc/mdn015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046245271
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1093/jnci/dji111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012123441
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1097/gco.0000000000000239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033356012
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1111/his.13528 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103268269
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1126/science.1279805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062471450
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1146/annurev-bioeng-112415-114722 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035945779
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1158/1078-0432.ccr-09-1692 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024329711
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1158/1078-0432.ccr-11-0099 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002263531
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1158/1078-0432.ccr-14-2780 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018580324
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1158/1078-0432.ccr-17-1029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091249666
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1158/1535-7163.mct-12-1107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007777257
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1172/jci45014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037799511
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1172/jci80420 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022292043
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.2005.03.3845 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204218
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2009.25.1991 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019828190
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1371/journal.pone.0075414 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039471372
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1517/14712590903319656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067588039
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1517/14728222.2010.519701 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019091862
249 rdf:type schema:CreativeWork
250 https://doi.org/10.4049/jimmunol.170.9.4854 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075280428
251 rdf:type schema:CreativeWork
252 https://doi.org/10.4161/cbt.6.9.4905 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072294727
253 rdf:type schema:CreativeWork
254 https://doi.org/10.7554/elife.30224 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100468486
255 rdf:type schema:CreativeWork
256 https://www.grid.ac/institutes/grid.417768.b schema:alternateName Center for Cancer Research
257 schema:name Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
260 schema:name MedImmune, LLC, Gaithersburg, MD, USA
261 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...